Dear Editor,

I have read the recent issue of the Journal of Immunotherapy and Precision Oncology, edited by Dr. Joud Hajjar, with immense enthusiasm. It describes “Cancer immunotherapy in immunocompromised patients: An often ignored, yet very vital puzzle!”[1]

These immunocompromised patients have a strikingly high susceptibility to develop a multitude of difficult-to-treat cancers.[2] I wish to expand on the imminent challenges and their pertinency in real-world practice.

In the last decade, immunotherapy, especially immune checkpoint inhibitors (ICIs), has revolutionized the cancer care. Cancer armamentarium is widened with the advent of ICI and the current oncologic indications of ICI encompass melanoma, lung cancer, genitourinary cancer, breast cancer, head and neck cancer, Merkel cell carcinoma, and others.

Notably, immunotherapeutic drugs are different from existing therapies in the mechanism of action, and there is a lack of cross-resistance. The recent evidence further emphasizes that immune evasion is important for carcinogenesis and certain arduous cancers preferentially develop in immunocompromised hosts.[2,3] The potential factors affecting this are the specific aspects of immune deficiency, the duration of immunosuppression, the immunomodulatory agents used, and the differences in patient populations. However, a more appealing and unique facet is the labyrinthine relationship between immunosuppression and cancer and their co-action with ICI agents driving the antitumor immune response.[2–4] Despite increasing indications and usage, we still have limited knowledge regarding the efficacy and safety in this exclusive immunosuppressed population as these patients are excluded from the clinical trials. Nonetheless, retrospective studies reported safe use of ICI in immunocompromised situations such as HIV infection or autoimmune disorders.[2,4,5] Some of the recent studies showed that ICIs are both safe and efficacious in HIV-positive patients with various malignancies, including Kaposi sarcoma, nonsmall cell lung cancer, melanoma, Merkel cell carcinoma, and Hodgkin's lymphoma.[2,4]

Clinical trials are underway to provide robust answers for the safety and efficacy of ICI in this population. Per contra, literature on ICI use in transplant recipients is discordant, where there is a real threat of possibly lethal-transplant rejections as high as 40%, physicians should be wary using ICI in this unique, data-free zone.[6]

Another similar population is patients on low-dose steroids for a variety of clinical conditions such as respiratory illnesses, fatigue, or brain metastasis. There is an argument against early or baseline use of steroids with ICI, which emerged from retrospective lung cancer cohorts.[7,8] In those cases, it is reasonable switching to alternative medications or decreasing corticosteroid dose (<10 mg) if feasible, recognizing that patients who are receiving steroids typically have more aggressive and extensive disease, which represents a possible confounding effect when interpreting these data. In contrast, late use of steroids in the treatment course may confer improved outcomes, perhaps reflecting the evidence linking immune-related adverse events and efficacy of ICI.[9,10]

I highly commend Dr. Hajjar for lighting up this crucial and often ignored controversy![1]

References

References
1.
Hajjar
J.
Cancer immunotherapy for the immunosuppressed: Dissecting the conundrum of safety and efficacy
.
J Immunother Precis Oncol
2019
;
2
:
53
4
.
2.
Adashek
JJ,
Junior
PN,
Galanina
N,
et al.
Remembering the forgotten child: The role of immune checkpoint inhibition in patients with human immunodeficiency virus and cancer
.
J Immunother Cancer
2019
;
7
:
130
.
3.
Hanahan
D,
Weinberg
RA.
Hallmarks of cancer: The next generation
.
Cell
2011
;
144
:
646
74
.
4.
Cook
MR,
Kim
C.
Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: A systematic review
.
JAMA Oncol
2019
;
5
:
1049
54
.
5.
Shah
M,
Jizzini
M,
Majzoub
I,
et al.
Safety of immune checkpoint blockade in patients with cancer and preexisting autoimmune diseases and/or chronic inflammatory disorders
.
J Immuno ther Precis Oncol
2019
;
2
:
59
64
.
6.
Fisher
J,
Zeitouni
N,
Fan
W,
et al.
Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review
.
J Am Acad Dermatol
2019
.
pii: S0190-9622(19)32317-5.
7.
Arbour
KC,
Mezquita
L,
Long
N,
et al.
Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer
.
J Clin Oncol
2018
;
36
:
2872
8
.
8.
Fucà
G,
Galli
G,
Poggi
M,
et al.
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors
.
ESMO Open
2019
;
4
:
e000457.
9.
Paz-Ares
L,
Luft
A,
Vicente
D,
et al.
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
.
N Engl J Med
2018
;
379
:
2040
51
.
10.
Fujii
T,
Colen
RR,
Bilen
MA,
et al.
Incidence of immune-related adverse events and its association with treatment outcomes: The MD Anderson Cancer Center experience
.
Invest New Drugs
2018
;
36
:
638
46
.

Financial support and sponsorship

The author disclosed no funding related to this article.

Conflicts of interest

The author disclosed no conflicts of interest related to this article.